Merck & Company (MRK)
NYSE:MRK

Merck & Company (MRK) Stock Forecast & Price Target

9,759 Followers
See the Price Targets and Ratings of:

MRK Analyst Ratings

Strong Buy
15Ratings
12 Buy
3 Hold
0 Sell
Based on 15 analysts giving stock ratings to
Merck
& Company
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

MRK Stock 12 Months Forecast

Average Price Target

$110.40
▲(0.54% Upside)
Based on 15 Wall Street analysts offering 12 month price targets for Merck & Company in the last 3 months. The average price target is $110.40 with a high forecast of $122.00 and a low forecast of $100.00. The average price target represents a 0.54% change from the last price of $109.81.
Highest Price Target$122.00Average Price Target$110.40Lowest Price Target$100.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Upgrade Banner
BMO Capital
$100.00
Hold
-8.93%
Downside
Reiterated
Merck (MRK) PT Raised to $100 at BMO CapitalBMO Capital analyst Evan David Seigerman raised the price target on Merck (NYSE: MRK) to $100.00 (from $91.00) while maintaining a Market Perform rating.
Atlantic Equities
$122.00
Buy
11.10%
Upside
Reiterated
Merck & Company (MRK) Receives a Buy from Atlantic Equities
Barclays
$110.00
Buy
0.17%
Upside
Reiterated
Barclays Maintains Overweight on Merck Co, Raises Price Target to $110
J.P. Morgan
$115.00
Buy
4.73%
Upside
Reiterated
Analysts' Opinions Are Mixed on These Healthcare Stocks: Insulet (NASDAQ: PODD), Resmed (NYSE: RMD) and Merck & Company (NYSE: MRK)
Cantor Fitzgerald
$120.00
Buy
9.28%
Upside
Reiterated
Merck (MRK) Pops After Beat-and-raise, Analyst Praises a Strong BeatThe robust sales for MRKs key products (KEYTRUDA, GARDASIL and others) underscore that growth across oncology, vaccines and animal health, as well as margin expansion opportunities, remain under-appreciated, in our view. Therefore, we believe multiple expansion should potentially drive MRK shares higher as earnings visibility improves beyond Keytrudas patent cliff in 2028+, the analyst said.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

MRK Financial Forecast

MRK Earnings Forecast
Next quarter’s earnings estimate for MRK is $1.53 with a range of $1.46 to $1.74. The previous quarter’s EPS was $1.85. MRK beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 52.48% of the time in the same period. In the last calendar year MRK has Outperformed its overall industry.
Next quarter’s earnings estimate for MRK is $1.53 with a range of $1.46 to $1.74. The previous quarter’s EPS was $1.85. MRK beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 52.48% of the time in the same period. In the last calendar year MRK has Outperformed its overall industry.
MRK Sales Forecast
Next quarter’s sales forecast for MRK is $13.67B with a range of $13.10B to $14.02B. The previous quarter’s sales results were $15.22B. MRK beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 42.84% of the time in the same period. In the last calendar year MRK has Outperformed its overall industry.
Next quarter’s sales forecast for MRK is $13.67B with a range of $13.10B to $14.02B. The previous quarter’s sales results were $15.22B. MRK beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 42.84% of the time in the same period. In the last calendar year MRK has Outperformed its overall industry.
MRK Analyst Recommendation Trends
In the current month, MRK has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MRK average analyst price target in the past 3 months is $110.40
In the current month, MRK has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MRK average analyst price target in the past 3 months is $110.40

MRK Stock Forecast FAQ

What is MRK’s average 12-month price target, according to analysts?
Based on analyst ratings, Merck & Company’s 12-month average price target is $110.40.
    What is MRK’s upside potential, based on the analysts’ average price target?
    Merck & Company has 0.54% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is MRK a Buy, Sell or Hold?
          Merck & Company has a conensus rating of Strong Buy which is based on 12 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Merck & Company’s price target?
            The average price target for Merck & Company is $110.40. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $122.00 ,the lowest forecast is $100.00. The average price target represents 0.54% Increase from the current price of $109.81.
              What do analysts say about Merck & Company?
              Merck & Company’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis